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Mycobacterium kansasii consists of 5 genetically distinct groups, of which 2 are associated 
with human disease. Determinants of the differences in virulence are unknown. Potential 
genes of interest are esat-6 and cfp-10, which are associated with virulence of 
Mycobacterium tuberculosis and Mycobacterium bovis but are lacking in bacille Calmette-
Guérin and in most environmental mycobacteria (M. kansasii is an exception). We 
investigated esat-6 and cfp-10 genes in 22 clinical and 14 environmental isolates of M. 
kansasii. Both were present in all isolates; each genetic group had its own characteristic 
Southern-blot pattern corresponding to a highly conserved fingerprint pattern. Nucleotide 
sequences of the genes differed 12.6% and 10.1%, respectively, from the M. tuberculosis 
homologues, but the deduced amino acid sequences were <5% different. In vitro, clinical and 
environmental genotypes of M. kansasii expressed CFP-10 and ESAT-6. Thus, virulence of 
M. kansasii is not directly related to esat-6 and cfp-10 genes or gene expression.  
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     Mycobacterium kansasii differs from most other environmental mycobacteria in its ability to 
cause disease in otherwise healthy and presumably immunocompetent persons, whereas the 
majority of the environmental mycobacteria are mainly associated with disease in 
immunocompromised individuals. Recognized risk factors for M. kansasii pneumonia are male 
sex, older age, smoking, and preexisting lung disease, but infection can occur in the absence 
of such risk factors. However, M. kansasii is a genetically heterogeneous species. On the 
basis of genotyping of the 16S 23S intergenic spacer region, which is located between the 
genes encoding the 16S and 23S ribosomal RNA genes, M. kansasii can be divided into 5 
genetically distinct groups (MKA-I through MKA-V). In previous studies, clinical isolates were 
mainly MKA-I and less often MKA-II, whereas environmental isolates were MKA-II, MKA-III, 
MKA-IV, or MKA-V [1 3]. The MKA-II genotype has been associated with infection in 
immunocompromised patients [4, 5], which could reflect a lower pathogenic potential than the 
MKA-I genotype. This partly overlapping dichotomy suggests the presence of genetically 
based differences in virulence between clinical and environmental M. kansasii strains, but no 
specific virulence genes have thus far been identified.  
     M. kansasii and Mycobacterium tuberculosis have several characteristics in common. They 
have been found, on the basis of the 16S 23S rRNA gene internal transcribed spacer (ITS) 
regions, to be phylogenetically related [6]. M. kansasii pneumonia is clinically and 
radiographically indistinguishable from classical pulmonary tuberculosis, which could reflect 
similarities in pathogenesis [7, 8]. Thus, to study potential virulence genes in M. kansasii, 
interesting genes would be those that are shared by M. tuberculosis and M. kansasii but that 
are lacking in other, less virulent environmental mycobacteria. In previous studies, 
comparative genomics between M. tuberculosis or pathogenic Mycobacterium bovis and the 
attenuated vaccine strain M. bovis bacille Calmette-Guérin (BCG) led to the identification of 
regions of difference, one of which, named "RD1," was found to be present in all M. 
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tuberculosis and pathogenic M. bovis strains but is lacking from all BCG strains [9, 10]. 
Several RD1-encoded proteins, of which ESAT-6 and CFP-10 have been studied most 
thoroughly, have been identified as potent T cell antigens in both animals and humans [11
13]. These antigens are currently under investigation for diagnostic use, to discriminate 
infection with M. tuberculosis from vaccination with BCG [14 18]. Besides potential diagnostic 
use, insertion and deletion studies have also demonstrated that RD1-encoded genes are 
important for mycobacterial virulence in experimental animals [19, 20] and that the loss of RD1 
was relevant for the attenuation of BCG [21].  
     Although the esat-6 and cfp-10 genes were lacking in most environmental mycobacteria 
and all BCG strains, they were demonstrated, by polymerase chain reaction (PCR) and/or 
Southern-blot analysis, to be in M. kansasii and Mycobacterium marinum, both of which can 
cause disease in apparently immunocompetent persons, and in the essentially apathogenic 
Mycobacterium szulgai, Mycobacterium flavescens, and Mycobacterium gastrii [11, 22 24]. 
Thus, esat-6 and cfp-10 represent suitable candidates for further investigation with regard to 
the virulence of M. kansasii. The present study aimed to investigate the esat-6 and cfp-10 
genes and gene expression in a large collection of clinical and environmental isolates of M. 
kansasii.  
MATERIALS AND METHODS  
     Mycobacterial isolates.     The esat-6 gene was studied in 30 different isolates of various 
mycobacterial species from the available collection at the National Institute of Public Health 
and the Environment (Bilthoven, The Netherlands) (table 1). For comparison, 1 BCG strain 
and M. tuberculosis H37 Rv were used. Next, a total of 36 M. kansasii isolates were studied. 
The origin and source of these isolates are listed in table 2. The isolates from the Czech 
Republic, Italy, Belgium, and Germany were retrieved from the strain collection of the 
Mycobacteriology Unit of the Institute of Tropical Medicine in Antwerp, Belgium. The isolates 
from The Netherlands originated from the strain collection of the Mycobacteria Department at 
the National Institute of Public Health and the Environment. 
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Table 1.      Isolates of various mycobacterial species tested with esat-6 restriction-
fragment length polymorphism. 
Species RIVM no. esat-6 RFLP 
M. kansasii gastrii Myc 4296 Positive, type IV 
M. kansasii gastrii 8842 Positive, type IV 
M. kansasii Atyp 889 Positive, type I 
M. kansasii Myc 212 Positive, type I 
M. marinum Myc 1580 Positive 
M. marinum ATCC 927 Negative 
M. marinum Mis 101 Positive 
M. marinum 9900037 Negative 
M. marinum 9900872 Negative 
M. avium paratuberculosis B8524 Negative 
M. avium paratuberculosis 316F Negative 
M. avium paratuberculosis Jeltema Negative 
M. avium hominissuis IWGMT 29 Negative 
M. avium hominissuis IWGMT 23 Negative 
M. avium avium IWGMT 17 Negative 
M. malmoënse J10792 Negative 
M. malmoënse S709 Negative 
M. xenopi Myc 527 Negative 
M. xenopi SCS 74/47 Negative 
M. gordonae ATCC 14470 Negative 
M. gordonae Myc 813 Positive 
M. gordonae-ureoliticum Myc 1064 Negative 
M. chelonei abscessus Myc 11303 Negative 
M. chelonei abscessus Myc 4662 Negative 
M. chelonei abcsessus Myc 11303 Negative 
M. peregrinum 11539 Negative 
M. peregrinum Myc 235 Negative 
M. fortuitum 11401 Negative 
M. fortuitum Hb5794 Negative 
M. xenopi Scs 74/47 Negative 
M. bovis BCG (Pasteur) ... Negative 
M. tuberculosis H37Rv ... Positive 
NOTE.     BCG, bacille Calmette-Guérin; RIVM no., identification code of the collection of 
nontuberculous mycobacteria at the National Institute of Public Health and the Environment.  
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Table 2.      Characteristics of 36 isolates of Mycobacterium kansasii. 
RIVM no. 
Year  
of isolation 
INNO LiPA 
(MKA) type 
esat-6 
RFLP 
MPTR 
RFLP 
esat-6  
sequence 
cfp-10  
sequence 
Source  
(patient code)a Country of isolation 
NLA000014036 1991 I I I I I Human (A) The Netherlands 
NLA000014051 1991 I I I I I Human (B) The Netherlands 
NLA000016152 1992 I I I I I Human (C) The Netherlands 
NLA000016483 1993 I I I I I Human (D) The Netherlands 
NLA000016529 1993 I I I I I Human (E) The Netherlands 
NLA000017001 1993 I I I I I Human (F) The Netherlands 
NLA000017097 1993 I I I I I Human (F) The Netherlands 
NLA000017010 1993 I I I I I Human (G) The Netherlands 
NLA000017202 1993 I I I I I Human (G) The Netherlands 
NLA000017098 1993 I I I I I Human (H) The Netherlands 
NLA009501577 1995 I I I I I Human (I) The Netherlands 
NLA009600029 1995 I I I I I Human (J) The Netherlands 
NLA009700554 1997 I I I I I Human (K) The Netherlands 
NLA009700576 1997 I I I I I Human (K) The Netherlands 
NLA009800036 1997 I I I I I Human (L) The Netherlands 
NLA009702392 1997 I I I I I Human (M) The Netherlands 
NLA009802295 1998 I I I ND ND Human (N) The Netherlands 
NLA009900419 1999 I I I I I Human (O) The Netherlands 
NLA009902193 1999 I I I I I Human (P) The Netherlands 
NLA000000893 2000 I I I I I Human (Q) The Netherlands 
NLA000101548 2001 I I I I I Human (R) The Netherlands 
NLA000001494 1995 I I I I I Shower water Czech Republic 
NLA000001495 1995 I I I I I Hot tap water Czech Republic 
NLA000001049 2000 II II II II II Human (S) The Netherlands 
NLA000001469 1994 II II II II II Environment Italy 
NLA000001471 1994 II II II II II Environment Italy 
NLA000001454 1991 III III III III III Tap water Belgium 
NLA000001493 1995 III ND ND IIIb IIIb Tap water Germany 
NLA000001457 1993 IV IV IV IV IV Biofilm Germany 
NLA000001458 1993 IV IV IV IV IV Tap water Germany 
NLA000001470 1994 IV ND ND IV IV Environment Italy 
NLA000001459 1995 V V V V V Tap water Belgium 
NLA000001464 1995 V V V V V Tap water Belgium 
NLA000001465 1996 V V V V V Tap water Belgium 
NLA000001461 1996 V V V V V Toilet Belgium 
NLA000001468 1996 V V V V V Soil Belgium 
NOTE.     ND, not determined; MPTR, major polymorphic tandem repeat; RIVM no., 
identification code of the collection of nontuberculous mycobacteria at the National Institute of 
Public Health and the Environment; RFLP, restriction-fragment length polymorphism.  
     
a
 Each capital denotes a different patient; 2 isolates from patients F, G, and K were 
included. 
     Characterization of the ITS subtypes.     ITS subtypes were determined by use of INNO-
LiPA Mycobacteria (Innogenetics), a DNA probe test that targets the 16S 23S rDNA ITS 
sequence, as described elsewhere [27]. This commercially available assay differentiates 
between M. kansasii group I and II and detects group III, IV, and V without discriminating 
among these ITS types. To differentiate between the latter types, a research LiPA strip (strip 
K) was used (Innogenetics; data not shown) that contained specific DNA probes for each ITS 
type. The M. kansasii isolates included all 5 genotypes.  
     Culture condition.     M. kansasii isolates were kept at -70°C in aliquots in Middlebrook 
7H9 supplemented with oleic acid albumin dextrose catalase and 15% glycerol until testing. 
Cultures were grown on Löwenstein-Jenssen medium at 35.5°C until sufficient growth was 
obtained for Western blotting and DNA isolation.  
     Southern-blot analysis.      Southern blots of the M. kansasii isolates were prepared as 
described elsewhere [25]. Briefly, DNA isolation was performed by use of the N-cetyl-N,N,N,-
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trimethyl ammonium bromide method. The purified DNA was digested with the restriction 
enzyme PvuII and subjected to electrophoresis. A mixture of a PvuII-digested supercoiled 
DNA ladder (Invitrogen) and HaeIII-digested phiX174 DNA was used as an internal DNA size 
marker. The DNA fragments were transferred to a DNA membrane. The DNA membranes 
were hybridized with the major polymorphic tandem repeat (MPTR) [26], and complete esat-6 
and cfp-10 genes were hybridized with the enhanced chemiluminescence (ECL) direct nucleic 
acid labeling and detection systems (Amersham Biosciences Europe). The probes of the 
esat-6 and cfp-10 genes were obtained by PCR by use of M. tuberculosis H37Rv DNA as 
target and were purified as described below. The primer sets used were Esa-12 CAT GAC 
AGA GCA GCA GTG and Esa-303 5 -GCC CTA TGC GAA CAT CCC-3  [11] for esat-6 and 
opBR78 5 -GTA GCC CGG GAT GGC AGA GAT GAA GAC CGA TGC C-3  and opBR103 5 -
TCA GAA GCC CAT TTG CGA GGA CAG C-3  for cfp-10. Computer-assisted analysis of the 
restriction-fragment length polymorphism (RFLP) patterns was done by use of BioNumerics 
software (version 3.0; Applied Maths).  
     Nucleotide sequencing.      Amplification of the esat-6 and cfp-10 genes was performed 
by use of 10 pmol of the primers described above. The primers, together with 50 ng of purified 
DNA, were added to 12.5 L of HotStarTaq Master mix (Qiagen), and the reaction volume was 
adjusted to 25 L with Milli-Q water (Millipore). The amplification mixture was subjected to 
initial denaturation for 3 min at 96°C; followed by 30 cycles at 96°C for 1 min, 60°C for 2 min, 
and 72°C for 3 min; and a final extension period at 72°C for 6 min. The PCR products were 
purified by use of a PCR purification kit (Qiagen). The nucleotide sequence of the esat-6 and 
cfp-10 genes was determined on both strands by direct sequencing of the PCR products on an 
automated capillary sequencer (model 310; Applied Biosystems) by use of fluorescence-
labeled dideoxynucleotide terminators (ABI PRISM BigDye Terminator cycle sequencing 
ready reaction kit; Applied Biosystems). Comparison of the sequence data of esat-6 and cfp-
10 of the environmental and clinical M. kansasii isolates with the M. tuberculosis sequence of 
H37Rv was performed by use of DNASTAR software (version 5.0; DNAstar).  
     Western-blot analysis.      Lysates of 2 clinical and 4 environmental M. kansasii isolates 
were obtained after culturing in modified Sauton medium at 37°C on an orbital shaker, as 
described elsewhere [28]. Bacteria were harvested after centrifugation, and the bacterial pellet 
was washed once in PBS (pH 7.4) and resuspended in a suspension that contained equal 
volumes of 0.1-mm glass beads and PBS with 1 mmol/L phenylmethylsulfonyl fluoride. The 
bacteria were thereafter lysed on a Mini-BeadBeater (Biospec Products), and the protein 
concentration was determined by the bicinchoninic acid method (Pierce). Ten micrograms of 
each protein lysate was applied for SDS-PAGE and Western-blot analysis, as described 
elsewhere [12]. As a reference, a short-term culture filtrate of M. tuberculosis was included 
[28]. ESAT-6 was detected by the monoclonal antibody HYB 76-8 [29], and CFP-10 was 
detected by the rabbit antibody K8493 raised against recombinant CFP-10, as described 
elsewhere [30]. The ECL Western-blotting system (Amersham Biosciences) was used for 
chemiluminescence detection of Western blots.  
RESULTS  
     esat-6 RFLP in different mycobacterial species.      Hybridization of a Southern blot 
containing DNA of a large variety of mycobacterial species with the esat-6 probe showed that 
the esat-6 or "esat-6 like" gene was present in M. tuberculosis, M. kansasii (MKA-I), M. 
kansasii gastrii (MKA-IV), and 2 of 5 M. marinum isolates (table 1). A weak but positive band 
was observed in 1 of 2 Mycobacterium gordonae isolates. The isolates were retested, with 
identical results. When the cfp-10 probe was used, all 5 M. marinum isolates gave a positive 
band. No esat-6 or esat-6 like genes were found in Mycobacterium avium hominissuis [31], M. 
avium avium, M. avium paratuberculosis, Mycobacterium malmoënse, Mycobacterium xenopi, 
Mycobacterium chelonei abscessus, Mycobacterium peregrinum, Mycobacterium fortuitum, or 
M. bovis BCG (Pasteur), confirming previous findings [11]. A representative selection of these 
findings is presented in figure 1. 
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Figure 1 Southern-blot analysis by use of the esat-6 probe of Mycobacterium 
tuberculosis on a selection of mycobacterial species (listed in table 1). National 
Institute of Public Health and the Environment nos. of the isolates are in parentheses 
after the species name. The apparent vague bands in lane 15 are artifacts. Lane 1, 
Mycobacterium bovis bacille Calmette-Guérin (P3); lanes 2 4, Mycobacterium marinum 
(Myc 1580, ATCC 927, Mis101); lanes 5 7, Mycobacterium avium paratuberculosis 
(B8524, 316F, Jeltema); lanes 8 and 10, M. avium hominissuis (IWGMT 29 and 23); lane 
9, M. avium avium (IWGMT 17); lanes 11 and 12, Mycobacterium kansasii gastrii (Myc 
4296 and 8842); lanes 13 and 14, M. kansasii (Atyp 889 and Myc 212); lanes 15 and 16, 
Mycobacterium malmoënse (J10792 and S709); lanes 17 and 18, Mycobacterium xenopi 
(Myc 527 and SCS 74/47); lanes 19 and 20, Mycobacterium gordonae (ATCC 14470 and 
Myc 813); lane 21, Mycobacterium chelonei (Myc 11303); and lane 22, Mycobacterium 
tuberculosis (H37Rv). 
 
     Association of MPTR-RFLP, esat-6 RFLP, and cfp-10 RFLP, respectively, among M. 
kansasii genotypes.      Southern-blot analysis of the esat-6 and cfp-10 genes demonstrated 
that a clear distinction could be made between clinical and environmental isolates of M. 
kansasii that corresponded to MPTR pattern distribution among the MKA genotypes. The 
MPTR-RFLP and esat-6 RFLP of a representative selection of isolates is shown in figure 2. 
Within each genotype, the pattern of the remaining isolates listed in table 2 were identical. For 
all isolates, the results obtained with cfp-10 RFLP were identical to those of the esat-6 RFLP. 
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Figure 2 Southern-blot analysis by use of the esat-6 probe of Mycobacterium 
tuberculosis and major polymorphic tandem-repeat (MPTR) fingerprinting in relation to 
the Mycobacterium kansasii genotype, according to the 16S 23S intergenic spacer 
region. Similar results were obtained with the cfp-10 probe (data not shown). 
 
     Gene sequencing.      Of the 5 different genotypes of M. kansasii, the nucleotide 
sequences of the PCR products of the esat-6 and cfp-10 genes were determined, including at 
least 2 isolates per genotype (figure 3A and 3B). Within each genotype, the sequences of 
esat-6 and cfp-10 genes were always 100% identical, except for MKA-III. Comparison of the 2 
MKA-III genotype isolates that were sequenced showed a 1-bp difference in both the esat-6 
and cfp-10 genes. When genotype MKA-I was used as a reference, the DNA sequences of the 
esat-6 gene (285 bp) differed between 0.3% (1 bp in MKA-IV) and 2.1% (6 bp in MKA-III), 
whereas the M. tuberculosis homologue differed by 10.5% (30 bp). For the cfp-10 gene (300 
bp), the observed differences varied between 0.7% (2 bp in MKA-II) and 1.3% (4 bp in 
genotypes MKA-IIIb, -IV, and -V), whereas the cfp-10 gene of M. tuberculosis differed by 10% 
(30 bp). The deduced amino acid sequences were aligned with the M. tuberculosis 
homologues, as is shown in figure 4A and 4B. The putative ESAT-6 and CFP-10 proteins of M. 
kansasii differed by only 2 or 3 and 5 or 7 amino acids, respectively, from the M. tuberculosis 
protein. Importantly, ESAT-6 and CFP-10 of the MKA-I and MKA-II genotypes were either 
identical to those of the environmental genotypes or differed by 2 aa at most. 
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Figure 3 Alignment of the nucleotide sequence of esat-6 (A) and cfp-10 (B) of 
Mycobacterium tuberculosis (used as reference) with the nucleotide sequences of the 
homologues of the 5 Mycobacterium kansasii genotypes. MKA-III and MKA-IIIb indicate 
2 different isolates of MKA-III that differed from each other by 1 bp in both genes. At 
least 2 isolates per genotype were studied, as specified in figure 4. 
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Figure 4 Alignment of the amino acid sequence of ESAT-6 (A) and CFP-10 
(B) of Mycobacterium tuberculosis with the deduced amino acid sequences of the 
homologues in Mycobacterium kansasii isolates. Nos. in parentheses after the 
MKA genotype indicate the no. of isolates that was studied. 
 
 
     The clinical M. kansasii isolates of MKA-I were isolated during the period between 1991 
and 2001. With regard to the nucleotide sequences of esat-6 and cfp-10, no difference was 
observed between isolates over time. Interestingly, the 2 water isolates from the Czech 
Republic that had previously been found to be MKA-I [32] showed identical MPTR RFLP and 
esat-6 and cfp-10 sequences as the clinical MKA-I isolates originating from The Netherlands. 
The clinical MKA-I strains that were isolated from patients residing in houses with the MKA-I 
water isolates were not included in the present study.  
     Expression of ESAT-6 and CFP-10 by clinical and environmental M. kansasii 
isolates.      Having demonstrated that there was no important difference between clinical and 
environmental isolates with regard to the presence of the esat-6 and cfp-10 genes or the 
deduced amino acid sequence of ESAT-6 and CFP-10, we next studied the expression of 
these genes during in vitro growth. Immunoblots of strain lysates by use of specific antibodies 
indicated that the ESAT-6 and CFP-10 proteins were expressed by clinical as well as 
environmental genotypes of M. kansasii. However, semiquantitative measurement by ECL 
indicated that the level of expression of ESAT-6 and CFP-10 was of a similar and high level in 
MKA-I and MKA-II isolates, whereas the expression of CFP-10 was relatively lower in MKA-III 
and MKA-IV isolates (table 3). 
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Table 3.      Western blot analysis of mycobacterial lysates. 
 
 
MKA  
genotype 
Source  
of isolate 
ESAT-6  
(HYB76 8a) 
CFP-10  
(K8493b) 
MTB STCFc  C +++ +++ 
1995-01577 I C +++ +++ 
1999-00419 I C +++ +++ 
2000-1494 I E +++ +++ 
2000-1469 II E +++ +++ 
2000-1454 III E +++ + 
2000-1457 IV E ++ (+) 
NOTE.     Results are expressed semiquantitatively: +++, strong band after 30 s; ++, strong 
band after 1 min; +, strong band after 3 min; (+), weak band after 3 min; -, no band after 5 min; 
C, clinical; E, environmental.  
     
a
 Monoclonal mouse anti ESAT-6 antibody. 
     
b
 Polyclonal rabbit anti CFP-10 antibody. 
     
c
 Short-term culture filtrate of M. tuberculosis. 
DISCUSSION  
     In the present study, 36 clinical and environmental isolates of M. kansasii were compared 
with regard to the esat-6 and cfp-10 genes and gene expression. The results indicate that 
homologues of the esat-6 and cfp-10 genes are present in clinical and environmental isolates 
of M. kansasii. Southern blots showed a characteristic pattern for each genotypically defined 
group of isolates, which suggests either that these genes reside on different segments of the 
genome or that differences exist between genotypes that are associated with changes in the 
target site for the restriction enzyme, causing variation in fragment size. During in vitro culture, 
clinical isolates produced roughly equivalent amounts of ESAT-6 and CFP-10, whereas the 
production of ESAT-6 exceeded that of CFP-10 for some of the environmental isolates. The 
nucleotide sequences of esat-6 and cfp-10 of M. kansasii were determined, including a 
number of isolates of each genotype, to assess inter- and intragenotypic polymorphisms. 
Within each genotype, the sequences were identical, with the exception of a single nucleotide 
difference between 2 MKA-III isolates. Compared with those of the M. tuberculosis homologue, 
the esat-6 sequences of the M. kansasii isolates were between 10.1% and 12.6% different, but 
the deduced amino acid sequences of ESAT-6 were nearly identical. The cfp-10 gene and the 
predicted protein of M. kansasii differed slightly more from the M. tuberculosis homologue, with 
a difference of 10% 10.3% at the nucleotide level and 5 or 7 aa at the protein level. The 
deduced amino acid sequences of both ESAT-6 and CFP-10 were identical in 4 of 5 MKA 
genotypes, with only ESAT-6 of MKA-V and CFP-10 of MKA-IV differing from the other 
genotypes. Thus, on the basis of the ESAT-6 and CFP-10 sequences, no definite distinction 
could be made between genotypes.  
     The notion that genes residing within the RD1 region are required for virulence has been 
strengthened by the results of a number of recent studies. Deletion of the esat-6 gene in M. 
bovis [19] or the deletion of RD1 in M. tuberculosis has been shown to decrease virulence in 
experimental animal models [20], whereas the reinsertion of RD1 into BCG or M. microti 
increases virulence [21]. Another study found no difference in virulence between BCG and 
BCG:esat-6 in mice [33]. Although the latter finding seems to contradict the results of the 
above-mentioned studies, the lack of virulence could be explained if both ESAT-6 and CFP-10 
are required to confer virulence. The results of our study indicate that, if ESAT-6 and CFP-10 
do play a role in the virulence of M. kansasii, it does not seem to be directly related to the 
presence of the genes, given that clinical isolates did not differ from environmental isolates in 
this respect and differed only partially with regard to in vitro protein expression. The functions 
of ESAT-6 and CFP-10 have only been partially elucidated. Two in vitro studies have found 
immunomodulating properties of CFP-10 on mouse mononuclear cells [34, 35]. Another study 
demonstrated a tight 1 : 1 molecular interaction between ESAT-6 and CFP-10, which indicates 
that the precise level of production of ESAT-6 relative to that of CFP-10 may be relevant for 
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the formation of an active complex [36]. ESAT-6 and CFP-10 do not possess typical signal 
sequences, and the availability of a mechanism for effective secretion could be a critical factor 
for pathogenicity. A recent study of M. tuberculosis mutants lacking RD1, the esat-6/cfp-10 
operon, or other specific RD1-encoded genes has led to a better understanding of the role 
played by RD1-encoded proteins in the pathogenesis of tuberculosis [37]. Secreted, but not 
intracellular, ESAT-6 was shown to be an important virulence factor, in that it causes cytolysis 
of pneumocytes. Interestingly, cfp-10, as well as several other genes in the RD1 region, were 
found to be involved with the secretion of ESAT-6, and a chaperone-like function would be 
consistent with the observed 1 : 1 molecular interaction of ESAT-6 and CFP-10. Another 
argument in favor of the notion that the functions of ESAT-6 and CFP-10 are closely related is 
that, at least in M. tuberculosis, the esat-6 and cfp-10 genes reside in the same operon and 
are regulated under the same promoter [13], which would be expected to result in the 
expression of equal amounts of both proteins. In that regard, our observation of lower 
secretion of CFP-10 relative to ESAT-6 in environmental isolates of genotype MKA-III and 
MKA-IV, but not of MKA-II, could be relevant for the lack of virulence of the former genotypes, 
which are considered to be apathogenic. If our finding of differences between clinical and 
environmental isolates of M. kansasii with regard to protein expression can be confirmed, 
more extended sequencing data will be required to evaluate whether the organization of these 
genes in M. kansasii is different from that in M. tuberculosis.  
     At the start of the study, esat-6 RFLP was performed on different mycobacterial species, to 
validate the method. Although the results mostly confirmed previously reported data on the 
species distribution of esat-6, several findings were new. In 3 previous reports, the esat-6 
and/or cfp-10 gene was found to be present in M. marinum, the negative isolate originating 
from cattle [11, 22, 23]. In our study, esat-6 was lacking in 3 of 5 M. marinum isolates, whereas 
cfp-10 was present in all of them. This finding could either indicate that esat-6 may not be 
essential for the virulence of M. marinum or, alternatively, that the esat-6 gene of some M. 
marinum isolates differs from the M. tuberculosis homologue to such an extent that it prevents 
hybridization of the probe, which will be the subject of further study. One previous study 
reported the absence of esat-6 in M. gordonae isolated from cattle [22], a species that is 
considered to be essentially apathogenic, whereas we found positive hybridization with esat-6 
in 1 of 2 isolates. This finding needs to be confirmed by PCR, to provide certainty that an esat-
6 like gene is indeed present in this species. Taking these findings together, virulence does 
not seem to be directly related to the presence of esat-6 or cfp-10.  
     Although the clinical and radiological presentations of pulmonary infection with M. kansasii 
and M. tuberculosis are indistinguishable, clinical and epidemiological differences exist 
between these infections. First, extrapulmonary infection with M. tuberculosis occurs in 
approximately one-sixth of all patients; it results from hematogenous spread early during the 
course of infection, whereas extrapulmonary localization of infection with M. kansasii is rare 
and occurs either as localized disease after traumatic inoculation or as part of disseminated 
disease in immunocompromised persons. Second, there is no proof of human transmission of 
M. kansasii, even though patients often excrete large numbers of M. kansasii in their sputum. 
Another difference is that infection with M. tuberculosis is characterized by an initial latent 
stage in the large majority of infected persons, the duration of which varies from weeks to 
many decades. The lifetime risk of progression to active tuberculosis disease is estimated to 
be 10%. In the absence of decreased cellular immunity due to HIV infection or 
immunosuppressive therapy, the factors underlying reactivation are often unknown. Whether a 
similar latent stage of infection with M. kansasii exists has not been studied, because no 
validated diagnostic test is available for that purpose. For the same reason, the proportion of 
infected persons who develop clinical illness caused by M. kansasii is not known.  
     The incidence of infection with M. kansasii differs by geographic region, but, in general, it is 
much lower than that with M. tuberculosis. Pulmonary infection can occur in apparently healthy 
persons but is diagnosed most frequently in persons with structural or functional lung 
abnormalities, whereas disseminated infection is seen almost exclusively in 
immunocompromised hosts. Thus, together with the lack of human transmission, M. kansasii 
does not seem to be as important a threat to individual and public health as is M. tuberculosis. 
M. kansasii is, nevertheless, an interesting pathogen to study, because only some of the 
genotypes of M. kansasii are associated with clinical illness, which indicates that both virulent 
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and avirulent strains are represented within the same species a rare characteristic in human 
pathogens. Detailed knowledge of the virulence factors of M. kansasii could be valuable to the 
understanding of the pathogenesis of mycobacterial infections in general and of tuberculosis in 
particular. This may aid the development of novel drugs and of an improved vaccine to target 
specific virulence mechanisms. In this regard, available data have indicated that vaccination 
with the immunodominant peptide of ESAT-6 as a subunit vaccine and with DNA containing 
the esat-6 gene confers partial protection against tuberculosis in mice [38, 39]. Immunization 
with a hybrid molecule of ESAT-6 and the immunodominant antigen 85B conferred protection 
against aerogenic infection with M. tuberculosis in mice at a level at least as high as BCG [40]. 
A recent study in guinea pigs confirmed and extended the findings in mice [41], and effective 
protection was found in a nonhuman primate model [42]. Further studies of the virulence 
factors of M. kansasii may provide additional important data to support the ongoing battle 
against tuberculosis.  
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